Hubei Biocause Pharmaceutical Co., Ltd. Sustainability Profile
Hubei Biocause Pharmaceutical Co., Ltd., commonly referred to as Biocause, is a prominent player in the pharmaceutical industry, headquartered in Hubei, China. Established in 2001, the company has made significant strides in the development and production of high-quality pharmaceutical products, particularly in the fields of antibiotics and anti-infectives. With a strong operational presence across various regions in China and beyond, Biocause is dedicated to innovation and excellence. The company’s core offerings include a diverse range of active pharmaceutical ingredients (APIs) and finished dosage forms, distinguished by their adherence to stringent quality standards and regulatory compliance. Recognised for its commitment to research and development, Hubei Biocause has achieved notable milestones, positioning itself as a trusted partner in the global pharmaceutical market.
DitchCarbon Score
How does Hubei Biocause Pharmaceutical Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hubei Biocause Pharmaceutical Co., Ltd.'s score of 7 is lower than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hubei Biocause Pharmaceutical Co., Ltd.'s reported carbon emissions
Hubei Biocause Pharmaceutical Co., Ltd., headquartered in China (CN), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments towards addressing climate change at this time. As there are no emissions figures or reduction initiatives available, it is important to note that Hubei Biocause Pharmaceutical Co., Ltd. may still be in the early stages of developing its climate strategy. The pharmaceutical industry is increasingly recognising the importance of sustainability and carbon footprint reduction, and it is anticipated that companies like Hubei Biocause will align with industry standards in the future. For now, the absence of data indicates that Hubei Biocause has not yet engaged in significant climate commitments or emissions reporting, which is a critical aspect of corporate responsibility in today's environmentally conscious market.
How Carbon Intensive is Hubei Biocause Pharmaceutical Co., Ltd.'s Industry?
How Carbon Intensive is Hubei Biocause Pharmaceutical Co., Ltd.'s Location?
Hubei Biocause Pharmaceutical Co., Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Hubei Biocause Pharmaceutical Co., Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
China Post Life Insurance Company Limited
Taiping Life Insurance Co., Ltd.
Minsheng Life Insurance Co. , Ltd
Tianan Life Insurance Company Limited of China
ABC Life Insurance Co., Ltd.
Hunan Er-Kang Pharmaceutical Co., Ltd
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.